Velarde Michael C, Zeng Zhaoyang, McQuown Jennelle R, Simmen Frank A, Simmen Rosalia C M
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72202, USA.
Mol Endocrinol. 2007 Dec;21(12):2988-3001. doi: 10.1210/me.2007-0242. Epub 2007 Aug 23.
Estrogen and progesterone, acting through their respective receptors and other nuclear proteins, exhibit opposing activities in target cells. We previously reported that Krüppel-like factor 9 (KLF9) cooperates with progesterone receptor (PR) to facilitate P-dependent gene transcription in uterine epithelial cells. Here we evaluated whether KLF9 may further support PR function by directly opposing estrogen receptor (ER) signaling. Using human Ishikawa endometrial epithelial cells, we showed that 17beta-estradiol (E(2))-dependent down-regulation of ERalpha expression was reversed by a small interfering RNA to KLF9. Transcription assays with the E(2)-sensitive 4x estrogen-responsive element-thymidine kinase-promoter-luciferase reporter gene demonstrated inhibition of ligand-dependent ERalpha transactivation with ectopic KLF9 expression. E(2) induced PR-A/B and PR-B isoform expression in the absence of effects on KLF9 levels. Addition of KLF9 small interfering RNA augmented E(2) induction of PR-A/B while abrogating that of PR-B, indicating selective E(2)-mediated inhibition of PR-A by KLF9. Chromatin immunoprecipitation of the ERalpha minimal promoter demonstrated KLF9 promotion of E(2)-dependent ERalpha association to a region containing functional GC-rich motifs. KLF9 inhibited the recruitment of the ERalpha coactivator specificity protein 1 (Sp1) to the PR proximal promoter region containing a half-estrogen responsive element and GC-rich sites, but had no effect on Sp1 association to the PR distal promoter region containing GC-rich sequences. In vivo association of KLF9 and Sp1, but not of ERalpha with KLF9 or Sp1, was observed in control and E(2)-treated cells. Our data identify KLF9 as a transcriptional repressor of ERalpha signaling and suggest that it may function at the node of PR and ER genomic pathways to influence cell proliferation.
雌激素和孕酮通过各自的受体及其他核蛋白发挥作用,在靶细胞中表现出相反的活性。我们之前报道过,Krüppel样因子9(KLF9)与孕酮受体(PR)协同作用,促进子宫上皮细胞中依赖孕酮的基因转录。在此,我们评估了KLF9是否可能通过直接对抗雌激素受体(ER)信号来进一步支持PR功能。利用人子宫内膜上皮细胞系Ishikawa,我们发现针对KLF9的小干扰RNA可逆转17β-雌二醇(E₂)依赖性的ERα表达下调。使用对E₂敏感的4x雌激素反应元件-胸苷激酶-启动子-荧光素酶报告基因进行的转录分析表明,异位表达KLF9可抑制配体依赖性的ERα反式激活。E₂在不影响KLF9水平的情况下诱导PR-A/B和PR-B异构体表达。添加KLF9小干扰RNA增强了E₂对PR-A/B的诱导作用,同时消除了对PR-B的诱导作用,表明KLF9对E₂介导的PR-A具有选择性抑制作用。对ERα最小启动子进行染色质免疫沉淀表明,KLF9促进E₂依赖性的ERα与包含功能性富含GC基序的区域结合。KLF9抑制ERα共激活因子特异性蛋白1(Sp1)募集到包含半雌激素反应元件和富含GC位点的PR近端启动子区域,但对Sp1与包含富含GC序列的PR远端启动子区域的结合没有影响。在对照细胞和经E₂处理的细胞中均观察到KLF9与Sp1在体内的结合,但未观察到ERα与KLF9或Sp1的结合。我们的数据确定KLF9是ERα信号的转录抑制因子,并表明它可能在PR和ER基因组途径的节点发挥作用,以影响细胞增殖。